BIOALLIANCE PHARMA

Paris, November 15, 2006 - BioAlliance Pharma SA (Euronext Paris – Code Isin :FR0010095596 - BIO), an emerging specialty pharmaceutical company focused onthe development of innovative therapeutics targeting drug resistance in cancer,HIV, and severe and opportunistic infections, announced today its revenues forQ3 2006.

(1) Until the end of 2005, BioAlliance Pharma's financial statements werepresented according to French accounting rules.

The EUR 102,000 revenues for Q3 derive from services supplied to Eurofins-VIRalliance(EVI,Inc.) as in Q1 and Q2 2006.

Main events:

1. Loramyc
   • On October 13, the Company announced it had received its firstMarketing Authorization. This was granted in France for Loramyc®,the first bioadhesive antifungal treatment for oropharyngeal candidiasisfor immuno-depressed patients. The Company has set up a team ofscientific staff under Florence Dupre, VP Sales and Marketing,to ensure effective launch preparations for the product. Team membershave strong experience in the hospital environment, which theyacquired while working for international pharmaceutical groups. Theircurrent priority is to meet hospital clinicians specializing in oncologyand infectious diseases. The team has already met with very positive reactionsfrom these specialists, thus confirming that there is a real need amongpatients.
     
   • On October 26, against the backdrop of these preparations, BioAllianceorganized a meeting of clinicians who had taken part in the clinicaldevelopment of Loramyc®. This symposium took place during ECC8, the 8thEuropean Congress of Chemotherapy and Infectiology held in Budapest .
     
   • Bertrand Dupont (Hôpital Necker, Paris , France ) gave a presentationon the clinical results of Loramyc® for candidiasis in patients infectedwith HIV, and René Jean Bensadoun (Centre hospitalier Antoine Lacassagne,Nice , France ), presented the results of trials on cancer patients whohad received radiotherapy with associated mucositis.
     
   • The antifungal profile of Loramyc® (miconazole Lauriad®) was thesubject of a recent comparative analysis completed according to FDA standardsby Professor Mahmoud Ghannoum (Center for Medical Mycology, UniversityHospital of Cleveland, USA). Prof Ghannoum presented the results at ECC8.These confirmed that miconazole, the main active ingredient of Loramyc®,remains a reference antifungal for the treatment of oropharyngeal candidiasis,compared to more recent treatments.
     
2. Appointment to the Supervisory Board
   • The Supervisory Board meeting of October 25 has co-opted GeorgesHibon as an independent member of the board, replacing Claude Stoufs(representative of venture capital firm, Capricorn).
     Hibon's pharmaceuticalexperience covers 18 years European and international activity at Merck,followed by eight years with Pasteur Mérieux Connaught,where his last position on leaving in 1998 was chairman for North America. He is currently an adviser to several companies and organizations in Europeand North America . His has accumulated more than 35 years experience inthe pharmaceutical and biotechnology industry. He has a degree from HEC.His other responsibilities include: board member of Cerep (France), Aphton,Inc. (US), and Biomérieux SA (France).
     “The arrival of Georges Hibonadds additional strengths to BioAlliance's board,” saidDominique Costantini , MD, President and CEO of BioAlliance Pharma. “Hebrings his remarkable breadth of industry vision and his sound experienceof worldwide pharmaceutical markets, especially in the US where the companywishes to develop significantly in the next few years,”

About BioAlliance Pharma

BioAlliance Pharma SA (Euronext Paris: BIO) is an emerging specialty pharmaceuticalcompany focused on the development of innovative therapeutics targeting drugresistance in cancer, HIV, and severe and opportunistic infections.

Specialty pharma targets the development and marketingof drugs for specialist markets and selected populations. This business model,unlike that of “big pharma” whichtargets general medicine, offers faster product development, lower R&D costs,smaller sales teams, and hence higher margins and fast growth.

The Company is developing three broad product rangesbased on the Lauriad(R) adhesive technology which allows an early and prolongedrelease of therapeutic agents at the site of the disease, the Transdrug® nanoparticletechnology designed specifically for intracellular targeting, and a New ChemicalEntities program focused on development of new drugs in oncology and HIV.

The Loramyc(R) (miconazole Lauriad(R)) 50 mg BioadhesiveBuccal Tablet has completed two Phase III clinical trials in Europe for treatmentof oropharyngeal candidiasis (OPC) in cancer and HIV patients. A pivotal PhaseIII trial of Loramyc(R) is ongoing in the US in 2006 for the same indication.A second product, acyclovir Lauriad(R), for the treatment of oral herpes, hascompleted a Phase I clinical trial in Europe . A Phase I/II trial in primaryliver cancer (hepatocellular carcinoma or HCC) utilizing the Company's doxorubicinTransdrug® nanoparticledelivery technology has been completed in Europe, and has been granted orphandrug status by the EMEA and the FDA.

Disclaimer

This communication expressly or implicitly contains certain forward-lookingstatements concerning BioAlliance Pharma SA and its business. Such statementsinvolve certain known and unknown risks, uncertainties and other factors,which could cause the actual results, financial condition, performance or achievementsof BioAlliance Pharma SA to be materially different from any future results,performance or achievements expressed or implied by such forward-lookingstatements. BioAlliance Pharma SA is providing this communication as of thisdate and does not undertake to update any forward-looking statements containedherein as a result of new information, future events or otherwise.
Fora discussion of risks and uncertainties which could cause actual results, financialcondition, performance or achievements of BioAlliance Pharma SA to differ fromthose contained in the forward-looking statements please refer to the RiskFactors (Facteurs de Risque) section of the reference document approved bythe AMF on 28 April 2006 under the number R. 06-042, which is available onthe AMF website http://www.amf-france.org or BioAlliance Pharma S.A.'s website http://www.bioalliancepharma.com .